For research use only
| Cat No. | ABC-X0249C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Host Cell | LNCap |
| Source Organ | Prostate |
| Disease | Carcinoma |
| Storage | Liquid Nitrogen |
The Xpress™ Human ARV7 over-expressing cell line (LNCap) serve as a prostate cancer model to explore resistance mechanisms to hormone therapy.
ARV7 LNCap Overexpression Cell Line is derived from androgen-responsive human prostate cancer LNCap cells. Stable ARV7 expression is achieved via lentiviral integration and validated by qRT-PCR. Cells are passaged below P20.
Target
ARV7 is a constitutively active androgen receptor splice variant, pivotal in castration-resistant prostate cancer and associated with treatment failure to enzalutamide or abiraterone. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0249C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Prostate |
| Disease | Carcinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | LNCap |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This overexpression model facilitates investigation of ARV7 in androgen signaling and resistance mechanisms, and is applicable for testing ARV7-targeted therapeutics.